Supraphysiological GLP-1 signaling by GLP-1A (GLP-1A) is exploited in the treatment of several metabolic disorders, such as type 2 diabetes, obesity, non-alcoholic fatty liver disease, and cardiovascular disease (1). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.